Literature DB >> 21438827

Off-target effects of tyrosine kinase inhibitors: Beauty or the Beast?

Ranran Zhang1, Thomas P Loughran.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 21438827     DOI： 10.3109/10428194.2011.560694

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  2 in total

1.  Dual protein kinase and nucleoside kinase modulators for rationally designed polypharmacology.

Authors:  Kahina Hammam; Magali Saez-Ayala; Etienne Rebuffet; Laurent Gros; Sophie Lopez; Berengere Hajem; Martine Humbert; Emilie Baudelet; Stephane Audebert; Stephane Betzi; Adrien Lugari; Sebastien Combes; Sebastien Letard; Nathalie Casteran; Colin Mansfield; Alain Moussy; Paulo De Sepulveda; Xavier Morelli; Patrice Dubreuil
Journal:  Nat Commun       Date:  2017-11-10       Impact factor: 14.919

2.  Lestaurtinib is a potent inhibitor of anaplastic thyroid cancer cell line models.

Authors:  Nicole Pinto; Stephenie D Prokopec; Frederick Vizeacoumar; Karlee Searle; Matthew Lowerison; Kara M Ruicci; John Yoo; Kevin Fung; Danielle MacNeil; Jim C Lacefield; Hon S Leong; Joe S Mymryk; John W Barrett; Alessandro Datti; Paul C Boutros; Anthony C Nichols
Journal:  PLoS One       Date:  2018-11-12       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.